RP-HPLC method for determination of Losartan Pottasium and Ferendopril erbumine in combined Tablet dosage form,

Abstract

A simple, fast, and precise reverse phase high performance liquid chromatographic method was developed and validated for the simultaneous estimation of losartan potassium and perindopril erbumine in its tablet form. The HPLC method involved by using HiQSil-C-18W ODS, (250 mm × 4.5 mm i.d.), 5 /m column and mobile phase was ACN: water in proportion of 50:50 v/v, pH adjusted to 3.2 ± 0.1 with 1 % o-phosphoric acid. The flow rate was 1.0 mLmin-1 and effluent was monitored at 210 nm. The retention time of losartan potassium and perindopril erbumine were eluted at 6.7 min and 4.5 min respectively. The method was validated in terms of linearity, precision, accuracy, limit of detection. The method was found to be linear in the range of 2-18 /gmL-1 for both the drug. The coefficient of variance for both the drug was more than 0.999. The mean percentage recovery was found to be 98.40 % for losartan potassium and 97.50 % for perindopril erbumine. The limits of quantification of losartan potassium and perindopril erbumine were found to be 0.109/gmL-1 and 0.041/gmL-1. The method has been successfully applied for determination of losartan potassium and perindopril erbumine in combined dosage form.